IRF9 and colorectal carcinoma: The Plexin A4/SEMA6D/IRF9 axis represents a promising therapeutic target, while the demonstrated efficacy of demethylating agents provides a strong rationale for incorporating epigenetic therapies into CRC treatment strategies, offering significant translational implications for clinical practice.